Nimesulide

  • Email
  • Help

The review of the liver-related safety of ‘systemic formulations’ of medicines containing nimesulide has been completed. The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) concluded that the benefits of these medicines still outweigh their risks, and that there is a need to restrict their use to ensure that the risk of patients developing liver problems is kept to a minimum. ‘Systemic formulations’ are medicines that are given as a treatment throughout the body, such as tablets, solutions and suppositories. The European Commission endorsed the CHMP opinion with a further restriction to limit the use of these medicines to ‘second-line’ (used when at least one other medicine has failed).

The European Commission issued a decision on 16 October 2009.

What is nimesulide?

Nimesulide is a non-selective non-steroidal anti-inflammatory drug (NSAID). It is used to treat acute (short-term) pain, and the symptoms of painful osteoarthritis (swelling in the joints) and primary dysmenorrhoea (period pains). Products containing nimesulide have been available since 1985 and are authorised in a number of Member States2. They are only available with a prescription. 


2Nimesulide is available as branded and generic medicines in the following Member States: Austria, Bulgaria, the Czech Republic, Cyprus, France, Greece, Hungary, Italy, Latvia, Lithuania, Malta, Poland, Portugal, Romania, Slovakia and Slovenia. Until December 2007, it was also available in Belgium. 

Why was nimesulide reviewed?

Nimesulide was reviewed by the CHMP in 2007 because of concerns with liver injury. The review was an article 107 procedure triggered by the decision of Ireland’s medicines regulatory authority in May 2007 to suspend the marketing authorisation for systemic nimesulide-containing medicines, mainly because of liver problems. The European Commission asked the Committee to prepare an opinion on whether the marketing authorisations for products containing nimesulide should be maintained, changed, suspended or withdrawn across the EU. 

At the end of the review in September 2007, the CHMP concluded that the available data did not support a suspension of all marketing authorisations in Europe. However, it recommended that some restrictions should be placed on the way these medicines are prescribed, including limiting the pack size to 30 doses, and that the information provided to doctors and patients be amended to limit the risk of liver injury3

The CHMP opinion adopted in September 2007 was transmitted to the European Commission so that it could issue a final decision. This process involves a consultation step with the Standing Committee for Medicinal Products for Human Use, a body of representatives from Member States. The Standing Committee could not reach an agreement, and, on 8 February 2008, the European Commission therefore asked the CHMP to further consider its opinion, taking new data on the risk of liver problems into account, in particularly new data supplied by Ireland, and looking at ways of minimising the risk associated with nimesulide. 


3The details on the actions taken by the Agency and of their outcome can be found in the question-and-answer document document published in September 2007.

Which data has the CHMP reviewed?

In the latest review, the CHMP has looked at all the reports of side effects affecting the liver in patients taking nimesulide reported since April 2007, including those from Ireland. The Committee has also reviewed the results of an Italian ‘simulation study’, carried out by the Italian medicines regulatory authority. This study used existing reports of the rate of side effects with all NSAIDs to simulate the possible effect that a suspension of nimesulide would have on the rates of side effects affecting the stomach and gut. The simulation took the impact of patients switching to alternative painkiller medicines into account. 

The Committed has also looked at whether Member States took additional measures to those proposed by the CHMP in September 2007, in order to minimise the risk of liver problems in patients using nimesulide-containing medicines.

What are the conclusions of the review?

Based on the additional information reviewed, the CHMP has not changed its conclusions from September 2007, namely that the benefits of systemic formulations of nimesulide still outweigh their risks, provided that the use of these medicines is restricted to ensure that the risk of patients developing liver problems is kept to a minimum. 

The CHMP noted that the only additional measures taken by Member States were changes to the prescription status or reimbursement levels for nimesulide-containing medicines. This suggested that the measures recommended in September 2007, including the changes to the prescribing information, were appropriate to reduce the risk of liver problems associated with nimesulide. 

However, the CHMP further concluded that the benefits and risks of nimesulide should be assessed in a wider context. This review should look at all of the potential risks of the medicine, especially the risk of side effects affecting the stomach and the gut, which were outside the scope of the original Article 107 procedure. This should be carried out in a separate ‘Article 31’ referral procedure. This type of referral is used when it is of ‘Community interest’ (for the benefit of all Member States) to have a common view on the benefit-risk balance of a medicine. 

Because of the severity of the side effects, the European Commission recommended that further measures be taken to ensure that the risk of these side effects is lowered. The European Commission noted that, in some Members States, nimesulide was restricted to second-line treatment. The restriction was therefore added into the prescribing information for nimesulide-containig medicines. The Commission also made it clear that the companies that market nimesulide-containing medicines should inform doctors about the medicines’ risks.

Name Language First published Last updated
Questions and answers on the outcome of the review of nimesulide-containing medicines BG = bălgarski 08/04/2010  
Questions and answers on the outcome of the review of nimesulide-containing medicines ES = español 08/04/2010  
Questions and answers on the outcome of the review of nimesulide-containing medicines CS = čeština 08/04/2010  
Questions and answers on the outcome of the review of nimesulide-containing medicines DA = dansk 08/04/2010  
Questions and answers on the outcome of the review of nimesulide-containing medicines DE = Deutsch 08/04/2010  
Questions and answers on the outcome of the review of nimesulide-containing medicines ET = eesti keel 08/04/2010  
Questions and answers on the outcome of the review of nimesulide-containing medicines EL = elliniká 08/04/2010  
Questions and answers on the outcome of the review of nimesulide-containing medicines EN = English 08/04/2010  
Questions and answers on the outcome of the review of nimesulide-containing medicines FR = français 08/04/2010  
Questions and answers on the outcome of the review of nimesulide-containing medicines IT = italiano 08/04/2010  
Questions and answers on the outcome of the review of nimesulide-containing medicines LV = latviešu valoda 08/04/2010  
Questions and answers on the outcome of the review of nimesulide-containing medicines LT = lietuvių kalba 08/04/2010  
Questions and answers on the outcome of the review of nimesulide-containing medicines HU = magyar 08/04/2010  
Questions and answers on the outcome of the review of nimesulide-containing medicines MT = Malti 08/04/2010  
Questions and answers on the outcome of the review of nimesulide-containing medicines NL = Nederlands 08/04/2010  
Questions and answers on the outcome of the review of nimesulide-containing medicines PL = polski 08/04/2010  
Questions and answers on the outcome of the review of nimesulide-containing medicines PT = português 08/04/2010  
Questions and answers on the outcome of the review of nimesulide-containing medicines RO = română 08/04/2010  
Questions and answers on the outcome of the review of nimesulide-containing medicines SK = slovenčina 08/04/2010  
Questions and answers on the outcome of the review of nimesulide-containing medicines SL = slovenščina 08/04/2010  
Questions and answers on the outcome of the review of nimesulide-containing medicines FI = suomi 08/04/2010  
Questions and answers on the outcome of the review of nimesulide-containing medicines SV = svenska 08/04/2010  

Key facts

Approved nameNimesulide
International non-proprietary name (INN) or common name

nimesulide

Associated namesAulin, Nimed
Class
Reference numberCHMP/430988/07
TypeArticle 107 procedures (prior to July 2012)

This type of procedure was triggered when a Member State varied, suspended or revoked the marketing authorisation for a medicine in its territory because of a safety issue. This procedure is no longer applicable and has been replaced by Article 107i.

StatusEuropean Commission final decision
Opinion date20/09/2007

All documents

Name Language First published Last updated
Questions and answers on the outcome of the review of nimesulide-containing medicines BG = bălgarski 08/04/2010  
Questions and answers on the outcome of the review of nimesulide-containing medicines ES = español 08/04/2010  
Questions and answers on the outcome of the review of nimesulide-containing medicines CS = čeština 08/04/2010  
Questions and answers on the outcome of the review of nimesulide-containing medicines DA = dansk 08/04/2010  
Questions and answers on the outcome of the review of nimesulide-containing medicines DE = Deutsch 08/04/2010  
Questions and answers on the outcome of the review of nimesulide-containing medicines ET = eesti keel 08/04/2010  
Questions and answers on the outcome of the review of nimesulide-containing medicines EL = elliniká 08/04/2010  
Questions and answers on the outcome of the review of nimesulide-containing medicines EN = English 08/04/2010  
Questions and answers on the outcome of the review of nimesulide-containing medicines FR = français 08/04/2010  
Questions and answers on the outcome of the review of nimesulide-containing medicines IT = italiano 08/04/2010  
Questions and answers on the outcome of the review of nimesulide-containing medicines LV = latviešu valoda 08/04/2010  
Questions and answers on the outcome of the review of nimesulide-containing medicines LT = lietuvių kalba 08/04/2010  
Questions and answers on the outcome of the review of nimesulide-containing medicines HU = magyar 08/04/2010  
Questions and answers on the outcome of the review of nimesulide-containing medicines MT = Malti 08/04/2010  
Questions and answers on the outcome of the review of nimesulide-containing medicines NL = Nederlands 08/04/2010  
Questions and answers on the outcome of the review of nimesulide-containing medicines PL = polski 08/04/2010  
Questions and answers on the outcome of the review of nimesulide-containing medicines PT = português 08/04/2010  
Questions and answers on the outcome of the review of nimesulide-containing medicines RO = română 08/04/2010  
Questions and answers on the outcome of the review of nimesulide-containing medicines SK = slovenčina 08/04/2010  
Questions and answers on the outcome of the review of nimesulide-containing medicines SL = slovenščina 08/04/2010  
Questions and answers on the outcome of the review of nimesulide-containing medicines FI = suomi 08/04/2010  
Questions and answers on the outcome of the review of nimesulide-containing medicines SV = svenska 08/04/2010  
Nimesulide - Article 107 procedures - Annex I BG = bălgarski 08/04/2010  
Nimesulide - Article 107 procedures - Annex I ES = español 08/04/2010  
Nimesulide - Article 107 procedures - Annex I CS = čeština 08/04/2010  
Nimesulide - Article 107 procedures - Annex I DA = dansk 08/04/2010  
Nimesulide - Article 107 procedures - Annex I DE = Deutsch 08/04/2010  
Nimesulide - Article 107 procedures - Annex I ET = eesti keel 08/04/2010  
Nimesulide - Article 107 procedures - Annex I EL = elliniká 08/04/2010  
Nimesulide - Article 107 procedures - Annex I EN = English 08/04/2010  
Nimesulide - Article 107 procedures - Annex I FR = français 08/04/2010  
Nimesulide - Article 107 procedures - Annex I IT = italiano 08/04/2010  
Nimesulide - Article 107 procedures - Annex I LV = latviešu valoda 08/04/2010  
Nimesulide - Article 107 procedures - Annex I LT = lietuvių kalba 08/04/2010  
Nimesulide - Article 107 procedures - Annex I HU = magyar 08/04/2010  
Nimesulide - Article 107 procedures - Annex I MT = Malti 08/04/2010  
Nimesulide - Article 107 procedures - Annex I NL = Nederlands 08/04/2010  
Nimesulide - Article 107 procedures - Annex I PL = polski 08/04/2010  
Nimesulide - Article 107 procedures - Annex I PT = português 08/04/2010  
Nimesulide - Article 107 procedures - Annex I RO = română 08/04/2010  
Nimesulide - Article 107 procedures - Annex I SK = slovenčina 08/04/2010  
Nimesulide - Article 107 procedures - Annex I SL = slovenščina 08/04/2010  
Nimesulide - Article 107 procedures - Annex I FI = suomi 08/04/2010  
Nimesulide - Article 107 procedures - Annex I SV = svenska 08/04/2010  
Nimesulide - Article 107 procedures - Annex II BG = bălgarski 08/04/2010  
Nimesulide - Article 107 procedures - Annex II ES = español 08/04/2010  
Nimesulide - Article 107 procedures - Annex II CS = čeština 08/04/2010  
Nimesulide - Article 107 procedures - Annex II DA = dansk 08/04/2010  
Nimesulide - Article 107 procedures - Annex II DE = Deutsch 08/04/2010  
Nimesulide - Article 107 procedures - Annex II ET = eesti keel 08/04/2010  
Nimesulide - Article 107 procedures - Annex II EL = elliniká 08/04/2010  
Nimesulide - Article 107 procedures - Annex II EN = English 08/04/2010  
Nimesulide - Article 107 procedures - Annex II FR = français 08/04/2010  
Nimesulide - Article 107 procedures - Annex II IT = italiano 08/04/2010  
Nimesulide - Article 107 procedures - Annex II LV = latviešu valoda 08/04/2010  
Nimesulide - Article 107 procedures - Annex II LT = lietuvių kalba 08/04/2010  
Nimesulide - Article 107 procedures - Annex II HU = magyar 08/04/2010  
Nimesulide - Article 107 procedures - Annex II MT = Malti 08/04/2010  
Nimesulide - Article 107 procedures - Annex II NL = Nederlands 08/04/2010  
Nimesulide - Article 107 procedures - Annex II PL = polski 08/04/2010  
Nimesulide - Article 107 procedures - Annex II PT = português 08/04/2010  
Nimesulide - Article 107 procedures - Annex II RO = română 08/04/2010  
Nimesulide - Article 107 procedures - Annex II SK = slovenčina 08/04/2010  
Nimesulide - Article 107 procedures - Annex II SL = slovenščina 08/04/2010  
Nimesulide - Article 107 procedures - Annex II FI = suomi 08/04/2010  
Nimesulide - Article 107 procedures - Annex II SV = svenska 08/04/2010  
Nimesulide - Article 107 procedures - Annex III BG = bălgarski 08/04/2010  
Nimesulide - Article 107 procedures - Annex III ES = español 08/04/2010  
Nimesulide - Article 107 procedures - Annex III CS = čeština 08/04/2010  
Nimesulide - Article 107 procedures - Annex III DA = dansk 08/04/2010  
Nimesulide - Article 107 procedures - Annex III DE = Deutsch 08/04/2010  
Nimesulide - Article 107 procedures - Annex III ET = eesti keel 08/04/2010  
Nimesulide - Article 107 procedures - Annex III EL = elliniká 08/04/2010  
Nimesulide - Article 107 procedures - Annex III EN = English 08/04/2010  
Nimesulide - Article 107 procedures - Annex III FR = français 08/04/2010  
Nimesulide - Article 107 procedures - Annex III IT = italiano 08/04/2010  
Nimesulide - Article 107 procedures - Annex III LV = latviešu valoda 08/04/2010  
Nimesulide - Article 107 procedures - Annex III LT = lietuvių kalba 08/04/2010  
Nimesulide - Article 107 procedures - Annex III HU = magyar 08/04/2010  
Nimesulide - Article 107 procedures - Annex III MT = Malti 08/04/2010  
Nimesulide - Article 107 procedures - Annex III NL = Nederlands 08/04/2010  
Nimesulide - Article 107 procedures - Annex III PL = polski 08/04/2010  
Nimesulide - Article 107 procedures - Annex III PT = português 08/04/2010  
Nimesulide - Article 107 procedures - Annex III RO = română 08/04/2010  
Nimesulide - Article 107 procedures - Annex III SK = slovenčina 08/04/2010  
Nimesulide - Article 107 procedures - Annex III SL = slovenščina 08/04/2010  
Nimesulide - Article 107 procedures - Annex III FI = suomi 08/04/2010  
Nimesulide - Article 107 procedures - Annex III SV = svenska 08/04/2010  
Nimesulide - Article 107 procedures - Annex IV BG = bălgarski 08/04/2010  
Nimesulide - Article 107 procedures - Annex IV ES = español 08/04/2010  
Nimesulide - Article 107 procedures - Annex IV CS = čeština 08/04/2010  
Nimesulide - Article 107 procedures - Annex IV DA = dansk 08/04/2010  
Nimesulide - Article 107 procedures - Annex IV DE = Deutsch 08/04/2010  
Nimesulide - Article 107 procedures - Annex IV ET = eesti keel 08/04/2010  
Nimesulide - Article 107 procedures - Annex IV EL = elliniká 08/04/2010  
Nimesulide - Article 107 procedures - Annex IV EN = English 08/04/2010  
Nimesulide - Article 107 procedures - Annex IV FR = français 08/04/2010  
Nimesulide - Article 107 procedures - Annex IV IT = italiano 08/04/2010  
Nimesulide - Article 107 procedures - Annex IV LV = latviešu valoda 08/04/2010  
Nimesulide - Article 107 procedures - Annex IV LT = lietuvių kalba 08/04/2010  
Nimesulide - Article 107 procedures - Annex IV HU = magyar 08/04/2010  
Nimesulide - Article 107 procedures - Annex IV MT = Malti 08/04/2010  
Nimesulide - Article 107 procedures - Annex IV NL = Nederlands 08/04/2010  
Nimesulide - Article 107 procedures - Annex IV PL = polski 08/04/2010  
Nimesulide - Article 107 procedures - Annex IV PT = português 08/04/2010  
Nimesulide - Article 107 procedures - Annex IV RO = română 08/04/2010  
Nimesulide - Article 107 procedures - Annex IV SK = slovenčina 08/04/2010  
Nimesulide - Article 107 procedures - Annex IV SL = slovenščina 08/04/2010  
Nimesulide - Article 107 procedures - Annex IV FI = suomi 08/04/2010  
Nimesulide - Article 107 procedures - Annex IV SV = svenska 08/04/2010  
Nimesulide - Article 107 procedures - Annex V BG = bălgarski 08/04/2010  
Nimesulide - Article 107 procedures - Annex V ES = español 08/04/2010  
Nimesulide - Article 107 procedures - Annex V CS = čeština 08/04/2010  
Nimesulide - Article 107 procedures - Annex V DA = dansk 08/04/2010  
Nimesulide - Article 107 procedures - Annex V DE = Deutsch 08/04/2010  
Nimesulide - Article 107 procedures - Annex V ET = eesti keel 08/04/2010  
Nimesulide - Article 107 procedures - Annex V EL = elliniká 08/04/2010  
Nimesulide - Article 107 procedures - Annex V EN = English 08/04/2010  
Nimesulide - Article 107 procedures - Annex V FR = français 08/04/2010  
Nimesulide - Article 107 procedures - Annex V IT = italiano 08/04/2010  
Nimesulide - Article 107 procedures - Annex V LV = latviešu valoda 08/04/2010  
Nimesulide - Article 107 procedures - Annex V LT = lietuvių kalba 08/04/2010  
Nimesulide - Article 107 procedures - Annex V HU = magyar 08/04/2010  
Nimesulide - Article 107 procedures - Annex V MT = Malti 08/04/2010  
Nimesulide - Article 107 procedures - Annex V NL = Nederlands 08/04/2010  
Nimesulide - Article 107 procedures - Annex V PL = polski 08/04/2010  
Nimesulide - Article 107 procedures - Annex V PT = português 08/04/2010  
Nimesulide - Article 107 procedures - Annex V RO = română 08/04/2010  
Nimesulide - Article 107 procedures - Annex V SK = slovenčina 08/04/2010  
Nimesulide - Article 107 procedures - Annex V SL = slovenščina 08/04/2010  
Nimesulide - Article 107 procedures - Annex V FI = suomi 08/04/2010  
Nimesulide - Article 107 procedures - Annex V SV = svenska 08/04/2010  
Questions and answers on the Committee for Medicinal Products for Human Use recommendation on nimesulide-containing medicines (English only) 21/09/2007  

Document description

  • Questions and answers (Q&A) - easy-to-understand summary of key issues and Committee conclusions
  • Summary of Opinion - contains the CHMP opinion of the referred medicine(s)
  • List of the medicines affected by the referral (Annex I)
  • Scientific conclusions of the Committee (Annex II)

The following two documents are sometimes available:

  • Changes to the summary of product characteristics, labeling or package leaflet (also known as Annex III) - available when changes have been recommended by the Committee
  • Conditions of the marketing authorisation (also known as Annex IV) - available when the Committee recommends measures to be taken for the marketing authorisation(s) such as safety measures or extra studies

Current status:
European Commission final decision